This article summarizes a discussion at LSX Biopharm America on September 11. A panel of industry experts discussed ...

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.

People inherit two copies of each gene -; one from each parent -; an evolutionary fail-safe to ensure survival even when one of them doesn't function.